Entera Bio Future Growth
Future criteria checks 0/6
Entera Bio's revenue and earnings are forecast to decline at 80.3% and 89.7% per annum respectively while EPS is expected to decline by 58.2% per annum.
Key information
-89.7%
Earnings growth rate
-58.2%
EPS growth rate
| Biotechs earnings growth | 36.2% |
| Revenue growth rate | -80.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -28 | N/A | N/A | 1 |
| 12/31/2024 | 0 | -9 | N/A | N/A | 1 |
| 6/30/2024 | 0 | -9 | -7 | -7 | N/A |
| 3/31/2024 | N/A | -9 | -8 | -8 | N/A |
| 12/31/2023 | N/A | -9 | -7 | -7 | N/A |
| 9/30/2023 | 0 | -10 | -7 | -7 | N/A |
| 6/30/2023 | 0 | -11 | -8 | -8 | N/A |
| 3/31/2023 | 0 | -11 | -9 | -9 | N/A |
| 12/31/2022 | 0 | -13 | -13 | -12 | N/A |
| 9/30/2022 | 0 | -14 | -13 | -13 | N/A |
| 6/30/2022 | 0 | -14 | -12 | -12 | N/A |
| 3/31/2022 | 0 | -14 | -12 | -12 | N/A |
| 12/31/2021 | 1 | -12 | -9 | -9 | N/A |
| 9/30/2021 | 1 | -12 | -8 | -8 | N/A |
| 6/30/2021 | 1 | -10 | -9 | -9 | N/A |
| 3/31/2021 | 0 | -11 | -10 | -10 | N/A |
| 12/31/2020 | 0 | -11 | -11 | -11 | N/A |
| 9/30/2020 | 0 | -11 | -12 | -12 | N/A |
| 6/30/2020 | 0 | -13 | -11 | -11 | N/A |
| 3/31/2020 | 0 | -11 | -10 | -10 | N/A |
| 12/31/2019 | 0 | -11 | -9 | -9 | N/A |
| 9/30/2019 | 1 | -10 | -8 | -8 | N/A |
| 6/30/2019 | 1 | -12 | -9 | -9 | N/A |
| 3/31/2019 | 1 | -9 | -9 | -9 | N/A |
| 12/31/2018 | 1 | -10 | -10 | -10 | N/A |
| 9/30/2018 | N/A | -11 | -9 | -9 | N/A |
| 6/30/2018 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2018 | N/A | -13 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -11 | N/A | -5 | N/A |
| 9/30/2017 | N/A | -8 | N/A | -4 | N/A |
| 6/30/2017 | N/A | -6 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2016 | N/A | -1 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 5DT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 5DT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 5DT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 5DT's revenue is expected to decline over the next 3 years (-80.3% per year).
High Growth Revenue: 5DT's revenue is forecast to decline over the next 3 years (-80.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 5DT's Return on Equity is forecast to be high in 3 years time